• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

RCT Results: Hormonal vs Copper IUD for Emergency Contraception

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Kaiser et al. (AJOG, 2022) compared 1 year pregnancy and IUD continuation rates among emergency contraception users receiving the levonorgestrel 52 mg or the copper IUD

METHODS:

  • Participant-masked, randomized noninferiority trial
  • Participants
    • Individuals desiring an IUD for emergency contraception
  • Interventions
    • Levonorgestrel 52 mg IUD
    • Copper T380A IUD
  • Study design
    • Treatment allocation was revealed to participants at 1 month | Participants had option of discontinuing or switching IUDs
    • Intention to Treat
    • Analyses included Cox proportional-hazard models to assess associations with the primary outcomes
  • Primary outcomes
    • Continuation rates
    • Pregnancy rates
    • Reasons for discontinuation

RESULTS:

  • Levonorgestrel IUD: 327 participants | Copper IUD: 328 participants
  • At 1 year, pregnancy rates were similar between the groups
    • Levonorgestrel IUD: 2.8%
    • Copper IUD: 3.0%
    • RR 0.9 (95% CI, 0.4 to 2.2); P=0.82
  • Most pregnancies occurred in participants after IUD removal
    • There was only 1 device failure per group
  • 1-year continuation rates did not differ between groups
    • Levonorgestrel IUD: 62.4%
    • Copper IUD: 55.8%
    • RR 1.1 (95% CI, 1.0 to 1.2); P=0.09
  • Of those that discontinued use, there were more complaints of increased bleeding and cramping among copper IUD users

CONCLUSION:

  • There was no significant difference between levonorgestrel 52 mg IUD vs copper IUD use for emergency contraception
    • Pregnancy rates at 1 year were very low and similar between both IUD types
  • Approximately both IUD types had a 60% continuation rate at 1 year
  • The authors stay

This further supported the LNG 52-mg IUD as an important option for EC and showed favorable IUD continuation and pregnancy rates for 1 year for users of both IUD types after EC placement 

Learn More – Primary Sources:

One-year pregnancy and continuation rates after placement of levonorgestrel or copper intrauterine devices for emergency contraception: a randomized controlled trial

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

RAPID EC Trial Results: Levonorgestrel vs Copper IUD for Emergency Contraception
Can Copper and Levonorgestrel IUD Use Be Safely Extended?
Outcomes after Immediate Postpartum IUD Insertion

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site